PEPTIDE RESEARCH TOPIC

Semaglutide (Sema) Research Peptide

Browse structured Semaglutide information, research terminology, product documentation, comparisons, and common questions.

TOPIC OVERVIEW

About Semaglutide

Identity and names

Semaglutide is the formal active-compound name; Sema and Sema peptide are informal abbreviations.

  • Ozempic, Wegovy, and Rybelsus are product names for specific regulated formulations and should not be used as automatic synonyms for every semaglutide material.

Compound type

Semaglutide is a modified GLP-1 analogue with high sequence similarity to human GLP-1.

  • A fatty-acid side chain promotes albumin binding, while sequence changes reduce degradation by DPP-4 and extend exposure.

Mechanism

Semaglutide selectively activates the GLP-1 receptor.

  • Research examines glucose-dependent insulin secretion, glucagon regulation, appetite-related signaling, and changes in the rate of early post-meal gastric emptying.

Research focus and evidence

Its evidence base includes molecular studies, controlled human trials, and post-authorization data for named prescription products.

  • This category covers receptor pharmacology, structure, formulation, storage, analytical identity, and comparisons with related incretin agonists.
  • It also distinguishes active-ingredient identity from brand-specific delivery systems and product labeling.

Regulatory status and limits

Semaglutide is authorized only through particular products, indications, doses, and manufacturing controls.

  • Evidence from a regulated product cannot be transferred automatically to compounded or research-labeled material; identity, concentration, excipients, sterility, and legal status remain product-specific.
Topics covered
  • GLP-1 research terminology
  • compound and brand distinctions
  • storage and stability
  • purity documentation
  • comparisons with related agonists
Common names and related terms: semaglutide, sema, sema peptide
RESEARCH TRACKER

Semaglutide Development & Clinical Research

Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.

LAST VERIFIEDSeptember 30, 2026
Registered records767
Active studies353
Completed studies348
FDA-listed brands3
DeveloperNovo Nordisk
AliasesOzempic, Wegovy, Rybelsus
Biological targetsGLP-1 receptor
Development stageApproved medicine with ongoing Phase 4 research
Regulatory statusFDA-approved formulations exist

What current projects are studying

Diabetes Mellitus, Type 2Type 2 DiabetesCardiovascular DiseasesObesityPreDiabetesCoronary Artery DiseaseNon-diabetic ObesityAtrial Fibrillation (AF)
SELECTED CURRENT RESEARCH

Latest and important projects

Showing 5 of 353 active studies
ASCEND PLUSNCT05441267

A Study of Cardiovascular Events iN Diabetes Plus

Diabetes Mellitus, Type 2

Phase
Phase 4
Status
Active, not recruiting
Enrollment
21,296 Actual
Expected completion
Aug 17, 2048
Record updated
Jun 23, 2026
Lead sponsor
University of Oxford
STENO INTEN-CTNCT05700877

Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes

Type 2 Diabetes · Cardiovascular Diseases

Phase
Phase 4
Status
Recruiting
Enrollment
7,300 Estimated
Expected completion
Mar 1, 2029
Record updated
Feb 6, 2025
Lead sponsor
Per Løgstrup Poulsen
REGISTERED STUDYNCT06571383

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Obesity

Phase
Phase 4
Status
Active, not recruiting
Enrollment
500 Estimated
Expected completion
Nov 15, 2031
Record updated
Jun 2, 2026
Lead sponsor
Novo Nordisk A/S
REGISTERED STUDYNCT05119179

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

PreDiabetes

Phase
Phase 4
Status
Recruiting
Enrollment
300 Estimated
Expected completion
Oct 31, 2026
Record updated
Mar 17, 2026
Lead sponsor
The University of Texas Health Science Center, Houston
CASCADESNCT07254572

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

Coronary Artery Disease · PreDiabetes

Phase
Phase 4
Status
Recruiting
Enrollment
300 Estimated
Expected completion
Aug 1, 2029
Record updated
Nov 28, 2025
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Primary sources: ClinicalTrials.gov · FDA Drugs@FDA — Ozempic (semaglutide), NDA 209637Counts reflect a dated ClinicalTrials.gov intervention search. Selected current projects are shown for orientation; records require entity review before longitudinal comparisons.

Registry status does not establish safety, efficacy, or regulatory approval.

START HERE

Essential Semaglutide guides

SEMAGLUTIDE KNOWLEDGE ARTICLESPage 1 of 33
06
KNOWLEDGE ARTICLE

Semax Nasal Spray Side Effects: What to Know

Semax nasal spray side effects are usually mild, but headaches, nasal irritation and sleep problems can occur. Learn the risks and interactions.

↗
15
KNOWLEDGE ARTICLE

How Long Does It Take for Semaglutide to Work?

Semaglutide can start curbing appetite in 1-2 weeks, but full weight loss effects take 8-16 weeks. See a week-by-week timeline and what changes when.

↗
16
KNOWLEDGE ARTICLE

Semaglutide B12 Compound: What It Is and Safety

Semaglutide B12 compound combines a GLP-1 drug with vitamin B12. Learn what it is, typical doses, color, safety, and FDA status of these products.

↗
17
KNOWLEDGE ARTICLE

Semax Science Bio: Vendor Status and What to Know

Semax Science Bio was a go-to research peptide supplier that has since shut down. Here's what Semax is, how researchers source it now, and key safety facts.

↗
18
KNOWLEDGE ARTICLE

Semax Nootropic Depot: What Buyers Need to Know

Searching for semax nootropic depot? Learn what Semax is, how it's sold, nasal spray and injection forms, side effects, and how to verify vendor quality.

↗
20
KNOWLEDGE ARTICLE

Semaglutide Oral Dosage: Rybelsus Dosing Guide

Semaglutide oral dosage starts at 3 mg once daily, then 7 mg or 14 mg. See how Rybelsus tablets are taken, who they're for, and what to expect.

↗